A review on recent one pot multi-component synthesis and biological properties of a class of new class of chromenes, coumarines, chromeno-pyrimidines, pyrido-pyrimidine and quinazoline heterocycles

Abstract

The chromenes, coumarines, pyrido-pyrimidine and quinazolinecores possesses a vast number of biological activities such as anticancer, anti-malarial, anti-microbial, anti-fungal, anti-tubercular activities and the conventional classical synthetic methods have harsh conditions having multistep process. Currently, researchers are in searchof new methodology to eliminate the use of chemicals, solvents and catalysts, which are hazardous to human health as well as to environment.This review provides a concise overview of new dimensions of one pot multi-component synthetic approaches in designing chromenes, coumarines, pyrido-pyrimidine and quinazoline scaffolds . This review will give more scientific ideas to synthesis a variety of heterocyclic moieties in a new synthetic way following the one-pot multi-component method.

*Keywords:*Chromenes, Coumarines, Pyrido-pyrimidines and Quinazolines, 1,4-dihydropyridines, tetrazoloquinazolinones, One-pot reactions, Multicomponent synthesis



Graphical Abstract

Introduction

Coumarine or 2*H*-chromene-2-one is an organic colourless solid compound with sweet odour having a lactone like ring fused with a benzene ring. Coumarines are also a class of chromene molecues where sp^3 hybridized carbon atom of 2*H*-chromene moelecule is replaced by carbonyl (C=O) group having both chemical and pharmaceutical importance. Coumarins are widely spread in the nature and can be found in many plants as secondary metabolites.[1] There are several reported isolation process of coumarines from natural resources [2-16] and also there have methods of laboratory synthsis of both coumarine, substituted coumarines (**Fig.1.**) and other coumarine derivatives. Coumarins are another important class of heterocyclic compounds which contain a basic flavinoid like skeleton and have both natural and synthetic origin that show diverse pharmaceutical and biological activities.[17] As coumarin scaffolds are one of the important fused ring heterocyclic bioactive compounds, a considerable effort have been made by researchers towards the fruitful synthesis of these useful bio-active coumarine heterocycles.Coumarins can be derived from natural resources and scaffold can be used extensively in laboratory for generation of newer drug molecules. Their derivatives are no doubt a class of bioactive agents which show a broad range biological activities such as anti-inflamatory [18], anticancer [19], anti-tubercular [20], anti-viral [21], anti-fungal [22]. A varity of scientific research have been made towards the synthesis coumarin analogues to find their significant applications in the field of medicinal chemistry and a number of coumarin derivatives have been obtained by following famous reactions procedures such as Knoevenagel, Perkin, Reformatsky, Michael etc. [23] Some coumarine derivatives also showed excellent fluorescent properties and thus a series of coumarin based molecular probes are being used to investigate drug action in cellular biological researches.[24]

According to IUPAC systems of nomanclatures, benzopyran systems are generally known as chromenes.[25] There are two isomers of benzopyran such as chromene and isochromene and additionally there are several types of chromenes reported in literature depending upon its structural variation and presence of ring substitution. Out of nine carbons in the ring system,

eight carbons are sp^2 and one carbon is sp^3 hybridized and depending upon the position of sp^3 carbon with respect to ring oxygen naming of chromenes are done as 2*H*-, 3*H*- and 4*H*-chromenes and the replacement of sp^3 hybridized carbon by carbonyl group leads to make 2*H*-, 3*H*- and 4*H*-chromenone or chromone rings.[26-27] A list of various types of chromenes have been shown in (**Fig.2.)** containing triclic and tetracyclic rings also.



Fig.1. Diverse synthetic routes for the synthesis of coumarine structures



Fig.2. Different types of chromene scaffolds

Synthetic chromene derivatives possesses potent anticancer, antibacterial and antifungal, antirheumatic, anti-inflamatory properties and a vast number of chromene heterocycles are found to have significant biological activity and some of them are used as potent drugs.[28] A large number of potent bioactive chromene heterocycles are reported in literature having anti-HIV, anti-inflamatory, anti-toumour, antihepatitic, anticancer, anticoagulant and antagonist activities(**Fig.3.**).[29-43] Therefore, synthetic chemists are always motivated to synthesize such potent analogous for pharmaceutical activities [44-47].



Fig.3.Some important pharmaceutically active drug molecule containing chromene structural skeletons

Coumarins possess broad range of biological activities such as- antifungal, anti-bacterial, anti-inflammatory, anti-HIV, anticancer, antituberculosis, anticoagulant, antiviral and significant antioxidant activities (**Fig.4.)** [48-59]. Some coumarins are derived as acetylcholinesterase inhibitors and so are useful drug in Alzheimer disease treatment [60].



Fig.4.Some important pharmaceutically active drug molecule containing coumarine structural skeletons

Dihydro-dichromeno-pyridine-6,8-dione derivatives also contain coumarin scaffolds which are considered as one of the important fused ring heterocyclic bioactive compounds and thus a varity of scientific research have been made towards the targeted synthesis coumarin analogues to find their significant applications in the field of medicinal chemistry. Coumarins can be derived also from natural resources and scaffold can be used extensively for the preparation of derivatives and their derivatives have no doubt a broad range of biological activities such as anti-fungal,[61] anti-inflammatory,[62] anti-tubercular activities,[63] antiviral,[64] anticancer,[65] etc. A number of fused ring coumarin derivatives have been obtained by following conventional techniques using hazardous chemicals [66] and thus a new sustainable development in synthetic procedure is needed for the synthesis of dihydro-dichromeno-pyridine-6,8-dione derivatives as our targeted product.

Dihydro-chromeno-pyridines are important class of heterocyclic compounds containing a 1,4-dihydropyridine ring fused with chromene moiety. They are treated as polycyclic 1,4-dihydropyridines and as they also belongs to the class of 1,4-dihydropyridine family they have a broad range of biological importance due to the presence of both dihydropyridine ring and fused chromene ring in it.[67-68] Dihydro-chromeno-pyridines may contain two chromene rings fused with 1,4-dihydropyridine ring or it may contain one chromene ring fused with 1,4-dihydropyridine ring. Inspite of having several synthetic procedures of skeletons of 1,4-dihydropyridines there are few reported synthetic procedure for the synthesis of dihydro-chromeno-pyridines skeleton using various catalysts.

1,4-dihydropyridines are a class of heterocyclic compound having low molecular weight having both commercial and biolological importance. In 1882, the synthesis of a 1,4-dihydropyridines are three component cyclocondensation reaction of acetoacetic ester, aldehyde and ammonia and after that there several methods of synthesis of 1,4-dihydropyridine skeleton are innovated by researchers using various novel catalysts (**Fig.5.**).[69]



Fig.5. Diverse synthetic routes for the synthesis of 1,4-dihydropyridine structures

Due to the presence of both chromene moiety and dihydropyridine rings these dihydro-chromeno-pyridine molecules have both biological and pharmaceutical importance.(Figure IV.2) Due to the presence of two bioactive chromene and dihydropyridine moieties these types of bioactive compounds largely exhibit diverse activities such as antimicrobial, anticancer, antitumor, antimalarial and antidiarrheal effects.[70-81]



Fig.6.Some important pharmaceutically active drug molecule

The pyridopyrimidines a of class of heterocyclic organic compounds have 6–6 bicyclic systems containing two or three nitrogen atoms in both six-membered rings. The compounds are also named as diaza- or triaza-naphthalenes which shows the structure of all possible types of pyridopyrimidines such as 4*H*-Pyrido[1,2-*a*]pyrimidin, 1*H*-Pyrido[1,2c]pyrimidin, Pyrido[2,3-*d]*pyrimidin, Pyrido[3,2-*d*]pyrimidin, Pyrido[3,4-*d*]pyrimidin, Pyrido[4,3-*d*]pyrimidin. (**Fig.7.**). Inspite of being natual abundance of pyridopyriminines and their derivatives there are several reported methods of the synthesis of such kind of bicyclic-aza compounds.[82] Among these pyridopyrimidines, 4*H*-Pyrido[1,2-*a*]pyrimidin, 1*H*-Pyrido[1,2-*c*]pyrimidin show tatumeric effect in solid state and solution phase depend upon the pH

condition of the supporting medium and in acidic medium their structure acquires cationic characteristics and in basic medium the shows anionic character.[83]



Fig.7.Various types of pyrido-pyrimidine skeleton



Fig.8.Various types of fused pyrimidine skeleton

The compounds are generally basic in nature due to the presence of available donatable electron pairs over 'N'-atoms to protons and have broad range of biological importance in

medicinal and biochemistry fields. There are also examples of other fused ring pyrimidines such as chromeno[4,3-*d*]pyrido[1,2-*a*]pyrimidine, thieno-[2,3-*d*]pyrimidine, pyrano[2,3-*d*]pyrimidines, pyrazolo[3,4-*d*]thiazolo[3,2-*a*]pyrimidine, furo[2,3-*d*]pyrido[1,2-*a*]pyrimidines, pyrido[1,2-*a*]thiazolo[5,4-*e*]pyrimi -dines, pyrido[1,2-*a*]pyrimido[4,5-*d*]pyrimidin-5-one, pyrano[2,3-*d*]py-rido[1,2-*a*]pyrimidinones, pyrimido-thienopyrido[1,2-*a*]pyrimidinone, thieno[2,3-*d*]pyrido[1,2-*a*]pyrimidines, pyrazolo-pyrido[1,2-*a*]pyrimi-dines and isoxazolo-pyrido[1,2-*a*]pyrimidines (**Fig.8.**) have already been reported. Fused pyrimidines can act as interesting scaffolds and key structures in chemistry and medicine as they show diverse biological and medical properties.

Among several types pyridopyrimidines, pyrido[2,3-*d*]pyrimidines are the most abundance isomer in the literature and have wide range of biological activities. Pyrido[2,3-*d*]pyrimidines have anti-inflammatory, antihypertensive, anticancer, antimicrobial, analgesic, antiviral activity and with addition they also act as tyrosine kinase inhibitor , CDK4-inhibitor, and anti-diuretic drugs.[84-88] However, the pyrido[3,2-*d*]pyrimidine, pyrido[3,4-*d*]pyrimidines, pyrido[4,3-*d*]pyrimidines, Pyrido[1,2-*a*]pyrimidines, and pyrido[1,2-*c*]pyrimidines have also biological activities like pyrido[2,3-*d*]pyrimidines such as anti-inflammatory, antimicrobial activities anticancer, antimalarial, anti-psychotropic, antibacterial, antituberculars tyrosine-kinases inhibitor, antiallergic, anti-ulcer, CNS stimulant, urease inhibitor activities activities (**Fig.9.**).[89-97]



Fig.9.Some important pharmaceutically active drug molecule

Another important class of heterocyclic compound is fused ring tetrazole derivatives and tetrazole fused bicyclo aromatic compounds have prominent biological activity in various biological aspect. Tetrahydrotetrazolo[1,5-*a*] quinazolinones falls in the category of fused ring tetrazole derivatives and they are structurally analogous with tetrazolopyrimidines. Tetrazole fused pyrimidines have broad range of biological properties, including antimicrobial,[98] antituberculosis[99] and antidepressant,[100] activities. There are a few examples of methods reported for the synthesis of tetrazolopyrimidines which involve initial synthesis of base catalysed chalcones followed by cyclocondensation reaction with 5-aminotetrazole. Wang and co-workers had reported also the synthesis of dihydrotetrazolo[1,5-*a*]pyrimidines and tetrahydrotetrazolo[1,5-a] quinazolinones catalysed via heavy metal ion Hg^{2+} [101] moreover a variety of catalysts like Iodine,[102] TBBDA,[103] [bmim+][BF_4^-],[104] acetic acid,[105] di-isopropylammonium trifluoroacetate [106] had been used to mediate the reaction. It remains a challenging task to develop a greener route for the synthesis of a varity of tetrahydrotetrazolo[1,5-a]quinazolinones and isolation and purification of final products and therefore, we intended to develop an sustainable and convenient synthetic route for the synthesis of tetrahydrotetrazolo[1,5-*a*]quinazolinones.

Tetrazoles are a class of synthetic organic heterocyclic compound consisting five membered ring containing four nitrogen atoms and one carbon atoms. The first preparation of tetrazole was carried out from HCN and HN_3. There have different types of tetrazole depending upon



Fig.10. Structures of 3 types of tatumeric tetrazoles

the position of the double bond and the presence of substitution on Carban atom such as 1*H*,2*H*,3*H*-tetrazole, aminotertazoles, thiotetrazole and several synthetic methods of tetrazole skeletons are reported (**Fig.10., Fig.11.**)



Fig.11.Diverse synthetic routes for the synthesis of 1,4-dihydropyridine structures

Quinazolinones are generally oxidized derivatives of quinazolines and they are classified into five categories based on the substitution patterns of the ring system (**Fig.12.**). According to literature 4(3*H*)-quinazolinones are most abundant as natural products and 2(1*H*)-quinazolinones are predominantly a product of benzamides with nitriles.[107] In the most common approach for the synthesis of quinazolinone compounds 2-aminobenzoic acid is used as a precursor. There are other methods reported for the synthesis of various types of quinazolinones below. (**Fig.13.**)



Fig.12. Different types of quinazoline scaffolds



Fig.13. Different synthetic routes of quinazolinone skeleton

Tetrazoles have a broad range of biological activities such as antibacterial, antifungal, anticancer, analgesic, anti-inflamatory, anti-diabetic, antitubercular activities.[108-114]

Quinazolinone moiety is a building block for approximately naturally occurring alkaloids and quinazolinone derivatives have attracted significant attention due to their diverse pharmacological activities such as antimalarial, antimicrobial, anti-inflammatory, anticonvulsant, antihypertensive, anti-diabetic, cholinesterase inhibition and anticancer activities and kinase inhibitor properties (**Fig.14.**).[115-124]



Fig.14.Some important pharmaceutically active drug molecule

Methods for synthesis of chromene and coumarine derivatives

In 2009, Shaabani *et al*. reported a room-temperature based synthesis of benzo[g]chromene derivatives via one-pot multicomponent reaction of aldehyde, malononitrile with 2-hydroxynaphthalene-1,4-dione or 2,5- dihydroxycyclohexa-2,5-diene-1,4-dione in presence of base catalyst Et_3N in CH_3CN solvent (**Scheme 1.**). Then characteriozation of the products were done with ^{1}H and ^{13}C-NMR by the authors in their work. [125].



Scheme 1. One potsynthesis of benzo[g]chromene derivatives by Shaabani *et al.*

In 2013, Rajguru *et al*. had reported a synthetic procedure for the synthesis of 4*H*-chromenes using aromatic aldehyde, malononitrile and C-H activated pyran-2-one to synthesise 2-amino-4*H*-chromene derivatives (**Scheme 2.**). Then characteriozation of the products were done with ^{1}H and ^{13}C-NMR by the authors in their work.[126].



Scheme 2. One potsynthesis of chromene heterocycles derivatives by Rajguru *et al*.

In 2010, Khurana *et al*. reported a synthetic procedure for pyran annulated heterocycles in one pot using DBU catalyst at reflux condition using 4-hydroxycoumarin, 4-hydroxy-6-methylpyrone, 1-naphthol and 2-hydroxynaphthalene-1,4-dione, with good yields (**Scheme 3.**). Then characteriozation of the products were done with ^{1}H and ^{13}C-NMR by the authors in their work.[127]



Scheme 3. One potsynthesis of chromene heterocycles derivatives by Khurana *et al.*

In 2011, Khan *et al*. repoted a three-component condensation reactions between aromatic aldehydes, ethyl cyanoacetate or malononitrile and diverse C–H activated acidic compounds (Z) in the presence of catalytic amount of DMAP in ethanol under reflux conditions for the synthesis of chromenes (**Scheme 4.**). Then characteriozation of the products were done with ^{1}H and ^{13}C-NMR by the authors in their work.[128].



Scheme 4. One potsynthesis of chromene heterocycles derivatives by Khan *et.al*.

In 2013, Bihani *et al.* synthesized chromenes and annulated heterocycles using aldehyde, malononitrile and diverse C–H activated acidic compounds (Z) in presence of amberlyst-A21 in ethanolic medium at room temperature (**Scheme 5.**).Then characteriozation of the products were done with ^{1}H and ^{13}C-NMR by the authors in their work.[129]



Scheme 5. One pot synthesis of chromene heterocycles derivatives by Bihani *et al*.

In 2011, Chen *et al*. reported a three-component reaction between 4-hydroxycoumarin, aldehydes, and cyclic 1,3-dicarbonyl compounds in water at reflux condition to produce a series of 10,11-dihydrochromeno[4,3-*b*]chromene-6,8-(7*H*,9*H*)-dione derivatives in good yields task specific ionic liquid, short reaction time, easy product separation and purification (**Scheme 6.**). Then characteriozation of the products were done with ^{1}H and ^{13}C-NMR by the authors in their work.[130].



Scheme 6. One pot synthesis of chromene heterocycles derivatives by Chen *et al.*

In 2013, Pradhan *et al*. described the synthesis of a series of chromeno[4,3-*b*]chromene derivatives via three-component reaction of aldehydes, 1,3-diketones, and 4-hydroxycoumarin in aqueous medium under reflux condition by using a Lewis acid-surfactant-combined catalyst [$Fe(DS)_3$] (**Scheme 7.**). Then characteriozation of the products were done with ^{1}H and ^{13}C-NMR by the authors in their work.[131].



Scheme 7. One pot synthesis of chromene heterocycles derivatives by Pradhan *et al*.

In 2013, Deacamin *et al*. synthesized chromene derivatives via three component coupling of aldehydes, active methylene compounds, and C-H activated compounds (Z) like dimedone, 4-hydroxycoumarin, 2-hydroxynaphthalene-1,4-dione, activated phenols in the presence of potassium phthalimide-N-oxyl as organocatalyst in aqueous medium under reflux condition (**Scheme 8.**). Then characteriozation of the products were done with ^{1}H and ^{13}C-NMR by the authors in their work. [132].



Scheme 8. One pot synthesis of chromene heterocycles derivatives by Deacamin *et.al*.

In 2014, Bramhachari *et. al*. reported MCR synthesis of substituted chromene heterocycles via three-component condensation reaction of aldehydes, malononitrile, and C-H activated acidic compounds (Z) in aqueous ethanol using 20 mol% ammonium or sodium formate and 20 mol% urea as organo catalyst (**Scheme 9.**). Then characteriozation of the products were done with ^{1}H and ^{13}C-NMR by the authors in their work.[133]



Scheme 9. One potsynthesis of chromene heterocycles derivatives by Bramhachari *et.al*.

Methods for synthesis of pyrido-pyrimidine derivatives

In 2021, Jadhav.*et al*. synthesised pyrazolo[3,4-*b*]pyridine derivatives in excellent yields (92−94%) via one-pot multicomponent reaction method using aminouracils and aminopyrazoles, aldehyde, and acyl acetonitrile in presence of $[Et_3NH][HSO_4]$ under solvent-free conditions (**Scheme 10.**). Then characteriozation of the products were done with ^{1}H and ^{13}C-NMR by the authors in their work.[134]



Scheme10. One pot synthesis of pyrido-pyrimidine derivatives by Jadav *et.al.*

In 2013, Yang *et al*. reported a one-pot three-component reaction method for the synthesis of 4*H*-pyrido[1,2-*a*]pyrimidines by condensation of 2-aminopyridines, aldehydes, and ketones/ aldehydes in presence of CF_3COOH acid catalyst in toluene solvent (**Scheme 11.**). Then characteriozation of the products were done with ^{1}H and ^{13}C-NMR by the authors in their work. [135]



Scheme 11. One pot synthesis of pyrido-pyrimidine derivatives by Yang *et al*.

In 2014, Mohssenimehra *et al.* designed a synthesis for Novel pyrido[2,3-*d*]pyrimidine derivatives were synthesized via one-pot threevcomponent methodology taking 6-amino-2-(methylthio or ethylthio)pyrimidin-4(3*H*)-one, 2,2-dimethyl-1,3-dioxane-4,6-dione and aryl aldehydes using HAp-encapsulated-γ-Fe_2O_3 catalyst at 60^0C and under solvent-free conditions (**Scheme12.**). Then characteriozation of the products were done with ^{1}H and ^{13}C-NMR by the authors in their work.[136]



Scheme 12. One pot synthesis of pyrido-pyrimidine derivatives by Mohssenimehra *et.al.*

In 2007, Adib *et al*. had reported a new, one-pot and three-component synthesis of 4*H*-pyrido[1,2-*a]*pyrimidines by using isocyanides, alkynes and N-substituted-2-aminopyridines at room temperature condition (**Scheme 13.**). Then characteriozation of the products were done with ^{1}H and ^{13}C-NMR by the authors in their work.[137]



Scheme 13. One pot synthesis of pyrido-pyrimidine derivatives by Adib *et al.*

In 2011, Majumdar *et al.* had reported a mild and efficient synthetic method for the synthesis of pyrido[3,2-*d*]pyrimidine derivatives via three-component reaction between amines, aldehydes, and terminal unactivated alkynes in presence of using $BF_3.OEt_2$ as Lewis acid catalyst in one pot. The features of this procedure are mild reaction conditions, good to high yields, and shorter reaction time with operational simplicity (**Scheme 14.**). Then characteriozation of the products were done with ^{1}H and ^{13}C-NMR by the authors in their work.[138]



Scheme 14. One pot synthesis of pyrido-pyrimidine derivatives by Majumdar *et.al.*

In 2012, Abdolmohammadi *et al*. sythesised a series of pyrido[2,3-*d*]pyrimidines via one-pot three-component reaction between aminouracil, malononitrile and aromatic aldehydes. using catalytic amount of diammonium hydrogen phosphate (DAHP) in aqueous medium. The reaction proceeds via domino Knoevenagel-Michael-cyclization reactions to give the Pyrido[2,3-*d*]pyrimidine derivatives. (**Scheme 15**). Then characteriozation of the products were done with ^{1}H and ^{13}C-NMR by the authors in their work.[139]



Scheme 15. One pot synthesis of pyrido-pyrimidine derivatives by Abdolmohammadi *et al*.

In 2012, Kidwai *et al*. reported a synthetic procedure for the synthesis of pyrido[2,3-*d*]pyrimidines through environmentally benign process by the reaction of aldehyde, malononitrile, 5-amino-1,3-dimethylpyrimidine-2,4(1*H*,3*H*)-dione and utilizing Fe_3O_4

magnetic nanoparticles at 40^0C (**Scheme 16.**). Then characteriozation of the products were done with ^{1}H and ^{13}C-NMR by the authors in their work.[140]



Scheme 16. One pot synthesis of pyrido-pyrimidine derivatives by Kidwai *et.al*.

Recently in 2021 Khalaj *et al*. synthesized a variety of chromeno[4,3-*d*]pyrido[1,2-*a*]pyrimidine derivatives via the three-component condensation reaction between 4-hydroxycoumarin, aldehydes, and 2-aminopyridines in presence of $NiFe_2O_4$@SiO_2 grafted di(3-propylsulfonic acid) nanoparticles (**Scheme17.**).Then characteriozation of the products were done with ^{1}H and ^{13}C-NMR by the authors in their work.[141]



Scheme 17. One pot synthesis of pyrido-pyrimidine derivatives by Khalaj.*et.al*.

In 2018, Brahmachari *et.al*. applied an ultrasound-assisted methods for one-pot synthesis of a new series of pharmaceutically relevant and diversely functionalized 7-aryl/heteroarylchromeno[4,3-*d*]pyrido[1,2-*a*]pyrimidin-6(7*H*)-ones. A one pot three-component tandem reaction between 4-hydroxycoumarin, substituted aromatic aldehydes, and 2-aminopyridines were subjected for doing reaction in the presence of sulfamic acid as a catalyst (**Scheme 18.**). Then characteriozation of the products were done with ^{1}H and ^{13}C-NMR by the authors in their work.[142]



Scheme 18. One pot synthesis of pyrido-pyrimidine derivatives by Bramhachari et al.

Methods for synthesis of dihydro-dichromeno-pyridine-dione derivatives

In 2017, Zeynizadeh.*et al.* reported the synthesis of dihydro-dichromeno-pyridine-6,8-diones derivatives via one-pot condensation reaction of 1,3-diketones (ethyl acetoacetate or 4-hydroxycoumarin), aromatic aldehydes and aqueous ammonia in H_2O (70^0C) as a green solvent by using silica-layered nickel ferrite, ($NiFe_2O_4$@SiO_2@SO_3H) with excellent yield. (**Scheme 19.**).Then characteriozation of the products were done with ^{1}H and ^{13}C-NMR by the authors in their work. [143]



Scheme 19. One pot synthesis of dihydro-dichromeno-pyridine-6,8-diones derivatives Zeynizadeh *et al.*

In 2019, Gilanizadeh *et al*. had reported an efcient ecofriendly approach has been developed for one-pot multicomponent synthesis of dihydro-dichromeno-pyridine-6,8-diones derivatives by Tandem condensation of aromatic aldehydes, 4-hydroxycoumarin, and ammonium acetate by using heterogeneous Fe_3O_4@SiO_2@Ni–Zn–Fe hydrotalcite catalyst under solvent-free conditions (**Scheme 20.**). Then characteriozation of the products were done with ^{1}H and ^{13}C-NMR by the authors in their work.[144]



Scheme 20. One pot synthesis of dihydro-dichromeno-pyridine-6,8-diones derivatives Gilanizadeh *et.al*.

In 2004, Kidwai *et. al*. reported an ecofriendly approach for one-pot multicomponent synthesis of fused dihydro-dichromeno-pyridine-6,8-dione derivatives by condensation of aromatic aldehydes, 4-hydroxycoumarin, and ammonium acetate using UV light in presence of water solvent with considerable good product yield (**Scheme 21.**). Then characteriozation of the products were done with ^{1}H and ^{13}C-NMR by the authors in their work.[145]



Scheme 21. One pot synthesis of dihydro-dichromeno-pyridine-6,8-diones derivatives Kidwai.*et al.*

In 2020, Saffarian *et. al*. has reported a synthetic method of dihydro-dichromeno-pyridine-6,8-dione derivatives by using $Fe_3O_4@SiO_2@(CH_2)_3$-urea-quinoline sulfonic acid chloride, as nanomagnetic catalyst bearing under solvent free condition at 80^0C temperature with reasonable yield (**Scheme 22.**). Then characteriozation of the products were done with ^{1}H and ^{13}C-NMR by the authors in their work.[146]



Scheme 22. One pot synthesis of dihydro-dichromeno-pyridine-6,8-diones derivatives Saffarian *et al.*

In 2016, Shaabani *et. al.* reported a synthetic protocol for the synthesis of dihydro-dichromeno-pyridine-6,8-dione scaffolds with reasonable yield by using guanidinium-based sulfonic acid as a Brønsted acid as well as organocatalyst in water medium under reflux condition (**Scheme 23.**). Then characteriozation of the products were done with ^{1}H and ^{13}C-NMR by the authors in their work.[147]



Scheme 23. One pot synthesis of dihydro-dichromeno-pyridine-6,8-diones derivatives Shaabani *et al.*

In 2004, Brahmbhatt *et.al.* reported a synthetic protocol for the synthesis of dihydro-dichromeno-pyridine-6,8-diones with reasonable yield by using acetic acid as a Brønsted acid as well as organocatalyst as well as solvent at $130^{0}C$ temperature (**Scheme 24.**). Then characteriozation of the products were done with ^{1}H and ^{13}C-NMR by the authors in their work.[148]



Scheme 24. One pot synthesis of dihydro-dichromeno-pyridine-6,8-diones derivatives Brahmbhatt *et al.*

Methods of synthesis of tetrahydrotetrazolo[5,1-*b*]quinazolinone derivatives

In 2019, Basha *et.al.* reported a facile one-pot synthesis of tetrazolo[1,5-*a*]pyrimidine derivatives via a one pot three-component reaction between aldehydes, 5-aminotetrazole and 1,3-diketones in PEG-400 under microwave irradiation at 110^0C. (**Scheme 25.**). Then characteriozation of the products were done with ^{1}H and ^{13}C-NMR by the authors in their work. [149]



Scheme 25. One-pot synthesis of tetrazolo[1,5-*a*]pyrimidine derivatives by Basha.*et al.*

In 2019, Basha *et al.* also reported a facile synthesis of tetrahydrotetrazolo [5,1-*b*]quinazolinones via one one pot method by the reactions of aldehydes , 5-aminotetrazole and dimidone in presence of PEG-400 solvent under microwave irradiation at 110^0C temperature. (**Scheme 26**). Then characteriozation of the products were done with ^{1}H and ^{13}C-NMR by the authors in their work.[150]



Scheme 26. One-pot synthesis of tetrahydrotetrazolo [5,1-*b*]quinazolinones derivatives by Basha *et al*.

In 2019, Ghorbani□Vaghei *et al*. has reported a facile synthesis of tetrahydrotetrazolo[1,5□*b*]quinazolines and tetrahydrobenzo[*h*]-tetrazolo[5,1□b]quinazolines from the reaction of aldehydes, 5□aminotetrazole, and dimedone as cyclic 1,3 diketone in presence of Fe_3O_4@SiO_2@Propyl–ANDSA catalyst at 100^0C in H_2O/EtOH as the solvent. (**Scheme 27.**). Then characteriozation of the products were done with ^{1}H and ^{13}C-NMR by the authors in their work.[151]



Scheme27. A facile synthesis of tetrahydrotetrazolo[1,5□*b*]quinazolines and tetrahydrobenzo[*h*]tetrazolo[5,1□*b*] quinazolines by Ghorbani-Vaghei *et al*.

In 2012, Raju *et al*. has reported a facile synthesis of tetrazolo[1,5-a]pyrimidine derivatives from the reaction of aldehydes, 5□aminotetrazole, and ethylacetoacetate as acyclic 1,3 diketone in presence of a 1:1 mixture of N,N,N-triisopropylamine and CF_3COOH under microwave condition having reasonable yield (**Scheme 28.**).Then characteriozation of the products were done with ^{1}H and ^{13}C-NMR by the authors in their work. [152]



Scheme 28.A facile synthesis of tetrazolo[1,5-*a*]pyrimidine derivatives by Raju *et al*.

In 2010, Zeng *et al*. reported a novel reaction for the synthesis of dihydrotetrazolo[1,5-*a*]pyrimidines by the reaction of 5-aminotetrazole with aryl aldehydes and acetophenone catalyzed by iodine in presence of isopropyl alcohol under refluxing condition in one pot method (**Scheme 29.**).Then characteriozation of the products were done with ^{1}H and ^{13}C-NMR by the authors in their work. [153]



Scheme 29.A facile synthesis of dihydrotetrazolo[1,5-*a*]pyrimidines by Zeng *et.al*.

In 2010, Zeng *et al*. also reported methods for the synthesis of dihydrotetrazolo[1,5-*a*]pyrimidine and tetrahydrotetrazolo[5,1-*b*]quinazolinone derivatives in one pot method in presence of iodine in isopropyl alcohol under reflux condition (**Scheme 30.**).Then characteriozation of the products were done with ^{1}H and ^{13}C-NMR by the authors in their work. [154]



Scheme 30. Synthesis of dihydrotetrazolo[1,5-*a*]pyrimidine and tetrahydrotetrazolo[5,1-*b*]quinazolinone derivatives by Zeng *et al*.

In 2021, Hassankhani *et al*. reported a synthetic method for the synthesis of tetrahydrotetrazolo[5,1-b]quinazolinone derivatives by using synthesized Fe_3O_4@meso-C immobilized with activated 4-aminobenzenesulfonic acid as catalyst in presence of water at 80^0C with good yields (**Scheme 31.**). Then characteriozation of the products were done with ^{1}H and ^{13}C-NMR by the authors in their work. [155]



Scheme 31. Synthetis of tetrahydrotetrazolo[5,1-*b*]quinazolinonederivatives by Hassankhani *et.al.*

In 2017, Kour *et al*. reported facile synthetic methods for the synthesis of dihydrotetrazolo[1,5-*a*]pyrimidines and tetrahydrotetrazolo[1,5-*a*]quinazolinones via one pot multi-component method by the reaction of 5-aminotetrazole, aldehyde and active methylene compounds (e.g. acetophenone, alkylacetoacetates, dimedone) in presence of $AlCl_3$ catalyst under reflux condition in acetonitrile solvent with reasonable yields (**Scheme 32.**). Then characteriozation of the products were done with ^{1}H and ^{13}C-NMR by the authors in their work. [156]



Scheme 32: One pot synthesis of dihydrotetrazolo[1,5-*a*]pyrimidines and tetrahydrotetrazolo[1,5-*a*]quinazolinones by Kour *et al*.

Conclusion

This review isan overview of new dimensions of one pot multi-component synthetic approaches in designing chromenes, coumarines, pyrido-pyrimidine and quinazoline scaffolds. This paper will play an important role in providing scientific ideas to synthesis a variety of heterocyclic moieties in a new synthetic way following the one-pot multi-component method.

DISCLAIMER (ARTIFICIAL INTELLIGENCE)

Author(s) hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc) and text-to-image generators have been used during writing or editing of this manuscript.

References

[1] Seo W D, Kim J Y, Ryu H W, Kim J H, Han S I, Ra J E, K. H. Seo K H, Jang K C, Lee J H. J. Identification and characterisation of coumarins from the roots of Angelica dahurica and their inhibitory effects against cholinesterase. Funct. Foods. 2013;5:1421-1431.

[2] Iranshahi M, Kalategi F, Sahebkar A, Sardashti A, Schneider B. New sesquiterpene coumarins from the roots of Ferula flabelliloba. Pharm. Boil. 2010; 48:217-220.

[3] Bai Y, Li D, Zhou T, Qin N, Li Z, Yu Z, Hua H. Coumarins from the roots of Angelica dahurica with antioxidant and antiproliferative activities. J. Funct. Foods 2016, 20:453-462.

[4] Sakunpak A, Matsunami K, Otsuka H, Panichayupakaranant P. Isolation of new monoterpene coumarins from Micromelum minutum leaves and their cytotoxic activity against Leishmania major and cancer cells. Food Chem. 2013;139:458-463.

[5] Peng W W, Zheng Y Q, Chen Y S, Zhao S M, Ji C J, Tan N H. Coumarins from roots of Clausena excavate. J. Asian Nat. Prod. Res. 2013;15:215-220.

[6] Joshi K R, Devkota H P, Yahara S. Chemical Analysis of Flowers of Bombax ceiba from Nepal. Nat. Prod. Commun. 2013;8:583-584.

[7] Naseri M, H. Monsef-Esfehani H, Saeidnia S, Dastan D, Gohari A. Antioxidative coumarins from the roots of Ferulago subvelutina. Asian J. Chem. 2013; 25:1875-1878.

[8] Sukumaran S, Kiruba S, Mahesh M, Nisha S, Miller P Z, Ben C. Phytochemical constituents and antibacterial efficacy of the flowers of Peltophorum pterocarpum (DC.) Baker ex Heyne. Asian Pac. J. Trop. Med. 2011; 4:735-738.

[9] Kicel A, Wolbis M. Coumarines from the flowers of Trifolium repens. Chem. Nat. Compd. 2012;48:130-132.

[10] Wang S, Tang F, Yue Y, Yao X, Wei Q, Yu J. Simultaneous determination of 12 coumarins in bamboo leaves by HPLC. J. AOAC Int. 2013;96:942-946.

[11] Aziz S S S A, Sukari M A, Rahmani M, Kitajima M, Aimi N, Ahpandi N J. COUMARINS FROM MURRAYA PANICULATA (RUTACEAE) . Malays. J. Anal. Sci. 2010;14:1-5.

[12] Joselin J, Brintha T S S, Florence A R, Jeeva S. Asian Pac. J. Trop. Dis. 2012; 2:260-264.

[13] Nguyen P H, Zhao B T, Kim O , Lee J H, Choi J S, Min B S, Woo M H. J. Nat. Med. 2016;70:789-796.

[14] Petrul'ová-Poracká V, Repcak M, Vilkova M, Imrich J. Coumarins of Matricaria chamomilla L.: Aglycones and glycosides. Food Chem. 2013;141:54-59.

[15] Sun J, Yue Y D, Tang F, Guo X F. J. Asian Nat. Prod. Res. 2010;12:248-251.

[16] Cho J Y, Hwang T L, Chang T H, Lim Y P, Sung P J, Lee T H. J. J. Chen. Evaluation of physicochemical properties of plasma treated brown rice. Food Chem. 2012;135:74-79.

[17] Fylaktakidou K C, Hadjipavlou-Litinas D J, Litinas K E, Nicolaides D N. Natural and synthetic coumarin derivatives with anti-inflammatory/antioxidant activities. Curr. Pharm. Des. 2004;10:3813-3833.

[18] Grover J J, Jachak S M. Coumarins as privileged scaffold for anti-inflammatory drug development. RSC Adv. 2015;5:38892-38905.

[19] Thakur A, Singla R, Jaitak V. Coumarins as anticancer agents: A review on synthetic strategies, mechanism of action and SAR studies. Eur. J. Med. Chem. 2015;101:476-495.

[20] Hu Y Q, Xu Z, Zhang S, Wu X, Ding J W, Lv Z S, Feng L S. Recent developments of coumarin-containing derivatives and their anti-tubercular activity. Eur. J. Med. Chem. 2017;136:122-130.

[21] Hassan M Z, Osman H, Ali M A, Ahsan M J. Therapeutic potential of coumarins as antiviral agents. Eur. J. Med. Chem. 2016;123:236-255.

[22] Hu X L, Xu Z, Liu M L, Feng L S, Zhang G D. Recent developments of coumarin hybrids as anti-fungal agents. Curr. Top. Med. Chem. 2017;17:3219 3231.

[23] Beccalli E M, Contini A, Trimarco P. New synthetic approach to [1] benzopyrano [4, 3-*b*] pyridin-5-one derivatives. Tetrahedron Lett. 2004;45:3447-3449.

[24] Zhou Y, Zhang X, Yang S, Li Y, Qing Z, Zheng J, Li J, Yan R. Ratiometric Visualization of NO/H2S Cross-Talk in Living Cells and Tissues Using a Nitroxyl-Responsive Two-Photon Fluorescence Probe. Anal. Chem. 2017;89:4587-4594.

[25] El-Gaby M S A, Zahran M A, Ismail M M F, Ammar Y A. A novel synthesis of dibenzo [c, f] chromenes, dibenzo [c, h] chromenes and benzo [7, 8] chromeno [3, 4-*f*] isoindoles as antimicrobial agents. Farmaco. 2000;55:227 232.

[26] Raj V, Lee J. 2*H*/4*H*-Chromenes—A versatile biologically attractive Scaffold. Frontiers in Chemistry. 2020;8:623.

[27] Goel A, Ram V J. Natural and synthetic 2H-pyran-2-ones and their versatility in organic synthesis. Tetrahedron, 2009;65:7865-7913.

[28] Erichsen M N, Huynh T H V, Abrahamsen B, Bastlund J F, Bundgaard C, Monrad O, Jensen A B, Nielsen C W, Frydenvang K, Jensen A A, Bunch L. Structure−Activity Relationship Study of First Selective Inhibitor of Excitatory Amino Acid Transporter Subtype 1: 2-Amino-4-(4-methoxyphenyl)-7-(naphthalen-1-yl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene 3-carbonitrile (UCPH-101). J. Med. Chem. 2010;53:7180-7191.

[29] Berg A, Reiber K, Dorfelt H, Walther G, Schlegel B, Grafe U. Laccaridiones A and B, new protease inhibitors from Laccaria amethystea. J. Antibiot. 2000;53:1313-1316.

[30] Otoguro K, Shiomi K, Yamaguchi Y, Arai N, Sunazuka T, Masuma R , Iwai Y, Omura S. Arisugacins C and D, Novel Acetylcholinesterase Inhibitors and Their Related Novel Metabolites Produced by Penicillium sp. FO-4259-1. J. Antibiot. 2000;53.50-57.

[31] Xu Z Q, Hollingshead M G, Borgel S, Elder C, Khilevich A, Flavin M T. In vivo anti-HIV activity of (+)-calanolide A in the hollow fiber mouse model. Bioorg. Med. Chem. Lett. 1999;9:133-138.

[32] Almeida E R. Preclinical and clinical studies of lapachol and beta-lapachone. Open Nat. Prod. J. 2009;2:42-47.

[33] Makino M , Fujimoto Y. Flavanones from Baeckea frutescens. Phytochemistry.1999;50:273-277.

[34] Ray S, Majumder H K, Chakraborty A K, Mukhopadhyay S. Amarogentin, a Naturally Occurring Secoiridoid Glycoside and a Newly Recognized Inhibitor of Topoisomerase I from Leishmania donovani. J. Nat. Prod. 1996;59:27-29.

[35] Schmidt W, Beerhues L. Alternative pathways of xanthone biosynthesis in cell cultures of Hypericum androsaemum L.. FEBS Lett. 1997;420:143-146.

[36] Lin Y L, Shen C C, Huang Y J, Chang Y Y. Homoflavonoids from Ophioglossum petiolatum. J. Nat. Prod. 2005;68:381-384.

[37] Thomas N, Zachariah S M. Asian J. Pharm. Clin. Res. 2013;6:11-15.

[38] Brahmachari G, Jash S K, Rec. Pat. Biotechnol. 2014;8:3-16.

[39] Hufford C D, Oguntimein B O, Engen D V, Muthard D, Clardy J. Vafzelin and uvafzelin, novel constituents of Uvaria afzelii. J. Am. Chem. Soc. 1980;102:7365-7367.

[40] Herrera E, Barbas C. Vitamin E: action, metabolism and perspectives. J. Physiol. Biochem. 2001;57:43-56.

[41] Fuendjiep V, Nkengfack A E, Fomum Z T, Sondengam B L, Bodo B. J. Nat. Prod. 1998;61:380-383.

[42] Ito C, Itoigawa M, Mishina Y, Filho V C, Enjo F, Tokuda H, Nishino H, Furukawa H. Chemical Constituents of Calophyllum brasiliense. 2. Structure of Three New Coumarins and Cancer Chemopreventive Activity of 4-Substituted Coumarins. J. Nat. Prod. 2003;66:368-371.

[43] Wandji J, Fomum Z T, Tillequin F, Libot F, Koch M. Erysenegalenseins B and C, two new prenylated isoflavanones from Erythrina senegalensis. J. Nat. Prod. 1995;58:105-108.

[44] Erichsen M N, Huynh T H V, Abrahamsen B, Bastlund J F, Bundgaard C, Monrad O, Jensen A B, Nielsen C W, Frydenvang K, Jensen A A, Bunch L. Structure−Activity Relationship Study of First Selective Inhibitor of Excitatory Amino Acid Transporter Subtype 1: 2-Amino-4-(4-methoxyphenyl)-7-(naphthalen-1-yl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene 3-carbonitrile (UCPH-101). J. Med. Chem. 2010;53:7180-7191.

[45] Paliwal P K, Jetti S R, Jain S. Green approach towards the facile synthesis of dihydropyrano(*c*)chromene and pyrano[2,3-*d*]pyrimidine derivatives and their biological evaluation. Med. Chem. Res. 2013;22:2984-2990.

[46] Bhavanarushi S, Kanakaiah V, Yakaiah E, Saddanapu V, Addlagatta A, Rani J V. Synthesis, cytotoxic, and DNA binding studies of novel fluorinated condensed pyrano pyrazoles. Med. Chem. Res. 2013;22:2446-2454.

[47] Amr A G E, Mohamed A M, Mohamed S F, Abdel-Hafez N A, Hammam A E F G. Anticancer activities of some newly synthesized pyridine, pyrane, and pyrimidine derivatives. Bioorg. Med. Chem. 2006;14:5481-5488.

[48] Olmedo D, Sancho R, Bedoya L M, López-Pérez J L, Del Olmo E, Muñoz E, Alcami J, Gupta M P, Feliciano A S. 3-Phenylcoumarins as inhibitors of HIV-1 replication. Molecules. 2012;17:9245-9257.

[49] Al-Ayed A S. Synthesis, Spectroscopy and Electrochemis try of New 3-(5-Aryl-4,5 Dihydro-1H-Pyrazol-3-yl)-4-Hydroxy-2H-Chromene-2-One 4, 5 as a Novel Class of Potential Anti-bacterial and Antioxidant Derivatives. Int. J. Org. Chem. 2011;1:87-96.

[50] Al-Amiery A A, Al-Majedy Y K, Kadhum A A H, Mohamad A B. Novel macromolecules derived from coumarin: synthesis and antioxidant activity. Sci. Rep. 2015;5.11825.

[51] Chen L Z, Sun W W, Bo L, Wang J Q, Xiu C, Tang W J, Shi J B, Zhou H P, Liu X H. New arylpyrazoline-coumarins: Synthesis and anti-inflammatory activity. Eur. J. Med. Chem. 2017;138.170-181.

[52] Anand P, Singh B, Singh N. A review on coumarins as acetylcholinesterase inhibitors for Alzheimer’s disease. Bioorg. Med. Chem. 2012;20:1175-1180.

[53] Matos M J, Mura F, Vazquez-Rodriguez S, Borges F, Santana L, Uriarte E, Olea-Azar C. Study of coumarin-resveratrol hybrids as potent antioxidant compounds. Molecules. 2015;20:3290-3308.

[54] Abdou M M. Utility of 4-hydroxythiocoumarin in organic synthesis. Arab. J. Chem. 2017;10:S3955-S3965.

[55] Wijayabandara M D J, Choudhary M I, Adhikari A. P.Characterization of an anti-hyperglycemic coumarin from the fruits of Averrhoa. Ann. Sci. Sess. Fac. Med. Sci. 2015;2.

[56] Akoudad S, Darweesh S K, Leening M J, Koudstaal P J, Hofman A, Van Der Lugt A, Stricker B H, Ikram M A, Vernooij M W. Use of Coumarin Anticoagulants and Cerebral Microbleeds in the General Population. Stroke. 2014;45:3436-3439.

[57] Keri R S, Sasidhar B S, Nagaraja B M, Santos M A. Recent progress in the drug development of coumarin derivatives as potent antituberculosis agents. Eur. J. Med. Chem. 2015;100:257-259.

[58] Hassan M Z, Osman H , Ali M A, Ahsan M J, Ahsan M J. Therapeutic potential of coumarins as antiviral agents. Eur. J. Med. Chem. 2016;123:236-255.

[59] Emami S, Dadashpour S. Current developments of coumarin-based anti cancer agents in medicinal chemistry. Eur. J. Med. Chem. 2015;102:611-630.

[60] Razavi S F, Khoobi M, Nadri H, Sakhteman A, Moradi A, Emami S, Foroumadi A, Shafiee A. Synthesis and evaluation of 4-substituted coumarins as novel acetylcholinesterase inhibitors. Eur. J. Med. Chem. 2013;64:252-259.

[61] Hu X L, Xu Z, Liu M L, Feng L S, Zhang G D. Curr. Top. Med. Chem. 2017;17. [62] Grover J, Jachak S M. RSC Adv. 2015;5:38892-38905.

[63] Hu Y Q, Xu Z, Zhang S, Wu X, Ding J W, Lv Z S, Feng L S. Recent developments of coumarin-containing derivatives and their anti-tubercular activity. Eur. J. Med. Chem. 2017;136:122-130.

[64] Hassan M Z, Osman H, Ali M A, Ahsan M J. Therapeutic potential of coumarins as antiviral agents. Eur. J. Med. Chem. 2016;123:236-225.

[65] Thakur A, Singla R, Jaitak V. Coumarins as anticancer agents: A review on synthetic strategies, mechanism of action and SAR studies. Eur. J. Med. Chem. 2015;101:476-495.

[66] Beccalli E M, Contini A, Trimarco P. New synthetic approach to [1] benzopyrano [4, 3-*b*] pyridin-5-one derivatives. Tetrahedron Lett. 2004;45:3447-3449.

[67] Swarnalatha G, Prasanthi G, Sirisha N, Chetty C M. 1,4-dihydropyridines: a multtifunctional molecule - a review. Int. J. Chem. Tech. Res. 2011;3:75-89.

[68] Kontogiorgis C A, H-Litina D J. Synthesis and biological evaluation of novel coumarin derivatives with a 7-azomethine linkage. Bio. Med. Chem. Lett, 2004;14:611-614.

[69] Hantzsch A. Condensationsprodukte aus Aldehydammoniak und ketonartigen Verbindungen. Chem. Ber. 1881;14.1637-1638.

[70] Rewcastle G W, Atwell G J, Chambers D, Baguley B C, Denny W A. Potential antitumor agents. 46. Structure-activity relationships for acridine monosubstituted derivatives of the antitumor agent N-[2-(dimethylamino)ethyl]-9-aminoacridine-4-carboxamide. J. Med. Chem. 1986;29:472-477.

[71] Tanifum E A, Kots A Y, Choi B K, Murad F, Gilbertson S R. Novel pyridopyrimidine derivatives as inhibitors of stable toxin a (STa) induced cGMP synthesis. Bioorg. Med. Chem. Lett. 2009;19:3067-3071.

[72] El-Ashmawy M B, El-Sherbeny M A, El-Gohary N S. Synthesis and antitumor screening of new series of pyrimido-[4,5- *b*]quinolines and [1,2,4]triazolo[20 ,30 :3,4]pyrimido[6,5 b]quinolines. Med. Chem. Res. 2013;22:2724-2736.

[73] Girault S, Grellier P, Berecibar A, Maes L, Mouray E, Lemière P, Debreu M A, DavioudCharvet E, Sergheraert C. Antimalarial, antitrypanosomal, and antileishmanial activities and cytotoxicity of bis (9-amino-6-chloro-2 methoxyacridines): influence of the linker. J. Med. Chem. 2000;43:2646-2654.

[74] Samai S, Nandi G C, Chowdhury S, Singh M S. L-Proline catalyzed synthesis of densely functionalized pyrido[2,3-*d*]pyrimidines via three-component one-pot domino Knoevenagel aza-Diels–Alder reaction. Tetrahedron, 2011;67:5935-5941.

[75] Denny W A, Atwell G J, Baguley B C, Wakelin L P G. Potential antitumor agents. 48. 3' Dimethylamino derivatives of amsacrine: redox chemistry and in vivo solid tumor activity. J. Med. Chem. 1985;28:652-658.

[76] Nofal Z, El-Zahar M, El-Karim A. Novel coumarin derivatives with expected biological activity. Molecules, 2000;5.99-113.

[77] C. A. Kontogiorgis, D. J. Hadjipavlou-Litina. Synthesis and Antiinflammatory Activity of Coumarin Derivatives,. Journal of Medicinal Chemistry, 2005;48:6400–6408.

[78] Ojala T, Remes S, Haansuu P, Vuorela H, Hiltunen R, Haahtela K, Vuorela P. Antimicrobial activity of some coumarin containing herbal plants growing in Finland. Journal of Ethnopharmacology. 2000;73:299-305.

[79] Kadhum A A H, Al-Amiery A A, Musa A Y, Mohamad A B. The antioxidant activity of new coumarin derivatives. International Journal of Molecular Sciences. 2011;12:5747-5761.

[80] Lee S, Sivakumar K, Shin W S, Xie F, Wang Q. Synthesis and anti angiogenesis activity of coumarin derivatives. Bioorganic & Medicinal Chemistry Letters, 2006;16.

[81] Nasr T, Bondock S, Youns M. European Journal of Medicinal Chemistry. Anticancer activity of new coumarin substituted hydrazide–hydrazone derivatives. 2014;76:539-548.

[82] Swinbourne J F, Hunt H J, Klinkert G. Adv Heterocycl Chem. 1987;23.

[83] Koval'chukova O V, Mordovina N I, Kuz'mina N E, Nikitin S V, ZaItsev B E, Strashnova S B, Palkina K K. Crystal structure and spectral characteristics of 2-methyl-3-chloro-9 hydroxypyrido[1,2-*a*]pyrimidin-4-one and bis(2-methyl-3-chloro-9-hydroxypyrido[1,2 a]pyrimidin-4-onium) perchlorate. Crystallogr Rep.2004;49:792-797.

[84] Reddy M V R, Akula B, Cosenza S C, Athuluridivakar S, Mallireddigari M R, Pallela V R, Billa V K, Subbaiah D R C V, Bharathi E V, Carpio R V, Padgaonkar A, Baker S J, Reddy E P. Discovery of 8-Cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8 dihydro-pyrido[2,3-*d*]pyrimidine-6-carbonitrile (7x) as a Potent Inhibitor of Cyclin-Dependent Kinase 4 (CDK4) and AMPK-Related Kinase 5 (ARK5). J. Med. Chem., 2014;57:578-599.

[85] Palop J A, Plano D, Moreno E, Sanmartín C. Novel quinazoline and pyrido[2,3 *d*]pyrimidine derivatives and their hydroselenite salts as antitumoral agents. ARKIVOC. 2014;2:187-206.

[86] Khokhani K M, Gol R M, Khatri T T, Patel P K. Microwave and conventional synthesis of novel pyrido[2,3-*d*]pyrimidine scaffold as an antimicrobial agent. Chem. Biol. Interface. 2014;4:119-130.

[87] Mohamed N R, Abdelhalim M M, Khadrawyd Y A, Elmegeed G A, Abdel-Salam O M E. One-pot three-component synthesis of novel heterocyclic steroids as a central antioxidant and anti-inflammatory agents. Steroids. 2012;77:1469-1476.

[88] DeGoey D A, Betebenner D A, Grampovnik D J, Liu, D Pratt J K, Tufano M D, He W, Krishnan P, Pilot-Matias T J, Marsh K C, Molla A, Kempf D J, Maring C J. Discovery of pyrido [2, 3-*d*] pyrimidine-based inhibitors of HCV NS5A. Bioorg. Med. Chem. Lett. 2013;23:3627-3630.

[89] Colbry N L, Elslager E F, Werbel L M. Folate antagonists. 21. Synthesis and antimalarial properties of 2,4-diamino-6-(benzylamino)pyrido[3,2-*d*]pyrimidines. J. Med. Chem.1985;28:248-252.

[90] Smaill J B, Rewcastle G W, Loo J A, Greis K D, Chan O H, Reyner E L, Lipka E, Showalter H D H, Vincent P W, Elliott W L, Denny W A. Tyrosine Kinase Inhibitors. 17.

Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-*d*]pyrimidine-6-acrylamides Bearing Additional Solubilizing Functions. J. Med. Chem. 2000;43:1380-1397.

[91] Weia L, Malhotra S V. Synthesis and cytotoxicity evaluation of novel pyrido[3,4-*d*]pyrimidine derivatives as potential anticancer agents. Med. Chem. Commun. 2012;3:1250-1257.

[92] Daub H, Specht K, Ullrich A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat. Rev. Drug Discov. 2004;3:1001-1010.

[93] Mohamed A M, El-Sayed W A, Alsharari M A, Al-Qalawi H R M, Germoush M O. Anticancer activities of some newly synthesized pyrazole and pyrimidine derivatives. Arch. Pharm. Res. 2013;36:1055-1065.

[94] Rajesh S M, Kumar R S, Libertsen L A, Perumal S, Yogeeswari P, Sriram D. A green expedient synthesis of pyridopyrimidine-2-thiones and their antitubercular activity. Bioorg. Med. Chem. Lett. 2011;21:3012-3016.

[95] Khan B U. J. Autism. Dev. Disord. 1997;27.

[96] Molina P, Aller E, Lorengo A, Cremadis P L, Rioja I, Ubeda A, Terencio M C, Alcaraz M J. Solid-Phase Synthesis and Inhibitory Effects of Some Pyrido[1,2-*c*]pyrimidine Derivatives on Leukocyte Functions and Experimental Inflammation. J. Med. Chem. 2001;44.1011-1014.

[97] Oppegard L M, Streck K R, Rosen J D, Schwanz H A, Drlica K, Kerns R J, H. Hiasa H. Comparison of In Vitro Activities of Fluoroquinolone-Like 2,4- and 1,3-Diones. Antimicrob. Agents Chemother. 2010;54:3011-3014.

[98] Gein V L, Mishunin V V, Tsyplyakova E P, Vinokurova O V, Vakhrin M I. Synthesis and antifungal activity of 9-aryl-8-(2-thienyl)-4, 9 dihydrotetrazolo-[1′, 5′-1, 2] pyrimido [4, 5-*d*] pyridazin-5 (6 *h*)-ones. Pharm Chem J. 2011;45:536-538.

[99] Pereyaslavskaya E S, Potemkin V A, Bartashevich E V. Theoretical investigation of the antituberculosis activity of compounds of the dihydropyrimidine series. Pharm Chem J. 2008;42:622-625.

[100] Wang H L, Wei C X, Deng X Q, Li F L, Quan Z S. Synthesis and Evaluation on Anticonvulsant and Antidepressant Activities of 5□Alkoxy□tetrazolo[1,5□*a*]quinazolines. Arch Pharm. 2009;342:671-675.

[101] Xi-Cun Wang, Y Wei, Yu-Xia Da, Zhang Z, Zheng-Jun Quan. ONE-STEP SYNTHESIS OF TETRAZOLO[1,5-*a*]PYRIMIDINES BY CYCLIZATION REACTION OF DIHYDROPYRIMIDINE-2-THIONES WITH SODIUM AZIDE. Heterocycles. 2011;83:2811-2822.

[102] Li-Yan Z, C Cai. Iodine Catalyzed One-Pot Multicomponent Synthesis of a Library of Compounds Containing Tetrazolo[1,5-*a*]pyrimidine Core. J Comb Chem. 2010;12:35-40.

[103] Gein V L, Gein L F, Tsyplyakova E P, Panova O S. Synthesis of 6-Acyl 7-aryl-4,7-dihydrotetrazolo[1,5-*a*]pyrimidine-5-carboxylic acids and their methyl esters. Russ J Org Chem. 2007;43:1382-1386.

[104] Raju C, Madhaiyan K, Uma R, Sridhar R, Ramakrishna S. Antimicrobial and antioxidant activity evaluation of tetrazolo [1, 5-*a*] pyrimidines: A simple diisopropylammonium trifluoroacetate mediated synthesis. RSC Adv. 2012;2:11657-11663.

[105] Tuan-Jie L, Chang-Sheng Y, Chen-Xia Y, Xiang-Shan W, Shu-Jiang T. Ionic Liquid Mediated One-Pot Synthesis of 5-(Trifluoromethyl)-4,7-dihydrotetrazolo[1,5-*a*]pyrimidine Derivatives. Synth Commun, 2012;42:2728-2738.

[106] Ramin G V, Zahra T S, Mostafa A, Rahman K N. Mol Divers. 2013;17.

[107] Cooonnoly D J, Cusack D, O'Sullivan T P, Guiry P J. Synthesis of quinazolinones and quinazolines. Tetrahedron, 2005;61:10153-10202.

[108] Jedhe G S, Paul D, Gonnade R G, Santra M K, Hamel E, Nguyen T L, Sanjayan G J. Correlation of hydrogen-bonding propensity and anticancer profile of tetrazole-tethered combretastatin analogues. Bioorg. Med. Chem. Lett. 2013;23:4680-4684.

[109] Wu L. Synthesis and biological evaluation of novel 1,2-naphthoquinones possessing tetrazolo[1,5-*a*]pyrimidine scaffolds as potent antitumor agents. RSC Adv. 2015;5:24960-24965.

[110] Dougherty A M, Guo H, Westby G, Liu Y, Simsek E, Guo J T, Mehta A, Norton P, Gu B, Block T, Cuconati A. A substituted tetrahydro-tetrazolo pyrimidine is a specific and novel inhibitor of hepatitis B virus surface antigen secretion. Antimicrob. Agents. Chemother. 2007;51:4427-4437.

[111] Wang S B, Deng X Q, Zheng Y, Yuan Y P, Quan Z S, Guan L P. Synthesis and evaluation of anticonvulsant and antidepressant activities of 5-alkoxytetrazolo[1,5 *c*]thieno[2,3-*e*]pyrimidine derivatives. Eur. J. Med. Chem. 2012;56. 139-144.

[112] Pegklidou K, Koukoulitsa C, Nicolaou I, Demopoulos V J. Design and synthesis of novel series of pyrrole based chemotypes and their evaluation as selective aldose reductase inhibitors. A case of bioisosterism between a carboxylic acid moiety and that of a tetrazole. Bioorg. Med. Chem., 2010;18:2107-2114.

[113] Dave C G, Shah R D. Annellation of Triazole and Tetrazole Systems onto Pyrrolo[2,3 *d*]pyrimidines: Synthesis of Tetrazolo[1,5-*c*]-pyrrolo[3,2-*e*]-pyrimidines and Triazolo[1,5 *c*]pyrrolo-[3,2-*e*]pyrimidines as Potential Antibacterial Agents. Molecules. 2002;7:554-565.

[114] Hussein M, Ahmed O M. Regioselective one-pot synthesis and anti proliferative and apoptotic effects of some novel tetrazolo [1, 5-*a*] pyrimidine derivatives. Bioorg. Med. Chem. 2010;18:2639-2644.

[115] Verhaeghe P, Azas N, Gasquet M, Hutter S, Ducros C, Laget M, Rault S, Rathelot P, Vanelle P. Synthesis and antiplasmodial activity of new 4-aryl-2-trichloromethylquinazolines.Bioorganic & Medicinal Chemistry Letters. 2008;18:396-401.

[116] Kuyper L F, Baccanari D P, Jones M L, Hunter R N, Tansik R L, Joyner S S, Boytos C, Rudolph S K, Knick V, Wilson H R, Caddell J M, Friedman H S, Comley J C W, Stables J N. High-Affinity Inhibitors of Dihydrofolate Reductase: Antimicrobial and Anticancer Activities of 7,8-Dialkyl-1,3-diaminopyrrolo[3,2-*f*]quinazolines with Small Molecular Size. Journal of Medicinal Chemistry. 1996;39:892-903.

[117] Alagarsamy V, Solomon V R, Sheorey R V, Jayakumar R.3□(3□Ethylphenyl)□2□substituted hydrazino□3H□quinazolin□4□one Derivatives: New Class of Analgesic and Anti□Inflammatory Agents. Chemical Biology & Drug Design. 2009;73:471-479.

[118] Georgey H, Abdel-Gawad N, Abbas S. Synthesis and Anticonvulsant Activity of Some Quinazolin-4-(3*H*)-one Derivatives. Molecules. 2008;13:2557-2569.

[119] Ismail M A H, Barker S, Abau El Ella D A, Abouzid K A M, Toubar R A, Todd M H. Design and Synthesis of New Tetrazolyl- and Carboxy biphenylylmethyl-quinazolin-4-one Derivatives as Angiotensin II AT1 Receptor Antagonists. J. Medicinal Chemistry. 2006;49:1526-1535.

[120] Malamas M S, Millen J. Quinazolineacetic acids and related analogs as aldose reductase inhibitors. Journal of Medicinal Chemistry. 1991;34:1492 1503.

[121] Decker M. Novel inhibitors of acetyl-and butyrylcholinesterase derived from the alkaloids dehydroevodiamine and rutaecarpine. European Journal of Medicinal Chemistry. 2005;40:305-313.

[122] Giardin D, Martarelli D, Sagratini G, Angeli P, Ballinari D, Gulini U, Melchiorre C, Poggesi E, Pompei P. Doxazosin-Related α1-Adrenoceptor Antagonists With Prostate Antitumor Activity. Journal of Medicinal Chemistry. 2009;52:4951-4954.

[123] Gangjee A, Kothare M, Kisliuk R L. The synthesis of novel nonclassical reversed bridge quinazoline antifolates as inhibitors of thymidylate synthase. Journal of Heterocyclic Chemistry. 2000;37:1097-1102.

[124] Levitzky A. Protein kinase inhibitors as a therapeutic modality. Accounts of Chemical Research. 2003;36.462-469.

[125] Shaabani A, Ghadari R, Ghasemi S, Pedarpour M, Rezayan A H, Sarvary A, Ng S W. Novel One-Pot Three- and Pseudo-Five-Component Reactions: Synthesis of Functionalized Benzo[*g*]- and Dihydropyrano[2,3-*g*]chromene Derivatives. J. Comb. Chem. 2009;11.956-959.

[126] Rajguru D, Keshwal B S, Jain S. H6P2W18O62·18H2O: A green and reusable catalyst for one-pot synthesis of pyrano[4,3-*b*]pyrans in water. Chin. Chem. Lett. 2013;24:1033-1036.

[127] Khurana J M, Nand B, Saluja P. DBU: a highly efficient catalyst for one-pot synthesis of substituted 3,4-dihydropyrano[3,2-*c*]chromenes, dihydropyrano[4,3-*b*]pyranes, 2-amino-4*H* benzo[*h*]chromenes and 2-amino-4H benzo[*g*]chromenes in aqueous medium. Tetrahedron.2010;66:5637-5641.

[128] Khan A T, Lal M , Ali S, Khan Md M. One-pot three-component reaction for the synthesis of pyran annulated heterocyclic compounds using DMAP as a catalyst. Tetrahedron Lett. 2011;52:5327–5332.

[129] Bihani M, Bora P P, Bez G, Askari H. Amberlyst A21: A reusable solid catalyst for green synthesis of pyran annulated heterocycles at room temperature. C. R. Chimie. 2013;16.419-426.

[130] Chen Z, Zhu Q, Su W. A novel sulfonic acid functionalized ionic liquid catalyzed multicomponent synthesis of 10,11-dihydrochromeno[4,3-*b*]chromene-6,8(7*H*,9*H*)-dione derivatives in water. Tetrahedron Lett. 2011;52:2601-2604.

[131] Pradhan K, Paul S, Das A R. $Fe(DS)_3$, an efficient Lewis acid-surfactant-combined catalyst (LASC) for the one pot synthesis of chromeno[4,3-*b*]chromene derivatives by assembling the basic building blocks. Tetrahedron Lett. 2013;54:3105-3110.

[132] Dekamin M G, Eslami M, Maleki A. Potassium phthalimide-N-oxyl: a novel, efficient, and simple organocatalyst for the one-pot three-component synthesis of various 2-amino-4H chromene derivatives in water. Tetrahedron. 2013;69.1074-1085.

[133] Brahmachari G, Laskar S. Nano-Mgo-Catalyzed One-Pot Synthesis of Phosphonate Ester Functionalized 2-Amino-3-Cyano-4H-Chromene Scaffolds at Room Temperature. J. Heteroclyclic Chem. 2014;51:873-888.

[134] Jadhav C, Nipate A, Chate A, Gill C. Triethylammonium Hydrogen Sulfate $[Et_3NH][HSO_4]$-Catalyzed Rapid and Efficient Multicomponent Synthesis of Pyrido[2,3 *d*]pyrimidine and Pyrazolo[3,4-*b*]pyridine Hybrids. ACS Omega. 2021;6:18125-18225.

[135] Yang K, Xiang J, Bao G, Dang Q, Bai X. Synthesis of Highly Substituted 4*H*-Pyrido[1,2-*a*]pyrimidines via a One-Pot Three-Component Condensation Reaction. ACS Com. Sci. 2013;15:519–524.

[136] Mohssenimehra M, Mamaghania M, Shirinia F, Sheykhana M, Moghaddamb F A. One-pot synthesis of novel pyrido [2, 3-*d*] pyrimidines using HAp-encapsulated-γ-Fe_2O_3 supported sulfonic acid nanocatalyst under solvent-free conditions. Chinese Chemical Letters. 2014;25:1387-1391.

[137] Adib M, Sayahi M H, Ziyadi H, Bijanzadehb H R, Zhuc L. A new, one pot, three-component synthesis of 4*H*-pyrido [1, 2-*a*] pyrimidines, 4H-pyrimido [1, 2-*a*] pyrimidines, and 4*H*-pyrazino [1, 2-*a*] pyrimidines. Tetrahedron. 2007;63:11135-11140.

[138] Majumdar K C, Ponra S, Ghosh D. Efficient, one-pot synthesis of pyrido [3, 2-*d*] pyrimidine derivatives. Synthesis. 2011;7:1132-1136.

[139] Abdolmohammadi S, Balalaie S. An Efficient Synthesis of Pyrido[2,3-*d*]pyrimidine Derivatives via One-Pot Three-Component Reaction in Aqueous Media. International Journal of Organic Chemistry. 2012;2:7-14.

[140] Kidwai M, Jain A, Bhardwaj S. Magnetic nanoparticles catalyzed synthesis of diverse N-Heterocycles. Mol Divers. 2012;16.121-128

[141] Khalaj M, Taherkhani M, Kalhor M. Preparation of some chromeno[4,3-*d*]pyrido[1,2 *a*]pyrimidine derivatives by ultrasonic irradiation using $NiFe_2O_4$@SiO_2 grafted di(3-propylsulfonic acid) nanoparticles. New J. Chem. 2021;45:10718-10724.

[142] Brahmachari G, Karmakara I, Nurjamala K. Ultrasound-Assisted Expedient and Green Synthesis of a New Series of Diversely Functionalized 7-Aryl/heteroarylchromeno[4,3 *d*]pyrido[1,2-*a*]pyrimidin-6(7*H*)-ones via One-Pot Multicomponent Reaction under Sulfamic Acid Catalysis at Ambient Conditions. ACS Sustainable Chem. Eng.2018;6.11018-11028.

[143] Zeynizadeh B, Rahmani S, Eghbali E. Anchored sulfonic acid on silica layered $NiFe_2O_4$: a magnetically reusable nanocatalyst for Hantzsch synthesis of 1, 4-dihydropyridines. Polyhedron, 2017;168:57-66.

[144] Gilanizadeh M, Zeynizadeh B. Cascade synthesis of fused polycyclic dihydropyridines by Ni–Zn–Fe hydrotalcite (HT) immobilized on silica-coated magnetite as magnetically reusable nanocatalyst. Res Chem Intermed. 2019;45:2811-2825.

[145] M. Kidwai M, Kukreja S, Rastogi S, Singhal K, Mishra N K. An aqua mediated facile synthesis of conformationally restricted polycyclic dihydropyridines. Indian J. Chem. 2004;53B:605-609.

[146] Saffarian H, Karimi F, Yarie M, Zolfigol M A. Fe_3O_4@SiO_2@$(CH_2)_3$-urea-quinoline sulfonic acid chloride: A novel catalyst for the synthesis of coumarin containing 1,4 dihydropyridines. Journal of Molecular Structure. 2020;1224:129294.

[147] Shaabani A, Shaabani S, Seyyedhamzeh M, Sangachin M H, Hajishaabanha F. Guanidinium-based sulfonic acid: an efficient Brønsted acid organocatalyst for the synthesis of fused polycyclic dihydropyridines in water. Res Chem Intermed. 2016;42:7247-7256.

[148] Brahmbhatt D I, Pandya U R, Raolji G B. Synthesis of 4-aryl-1, 4 dihydro-dicoumarino [4, 3-b; 3', 4'-e] pyridines. Heterocyclic Communications. 2004;10:419-422.

[149] Basha S F, Prasad T N, Gudise V B, Kumar V S, Mulakayala N, Anwar S. An efficient, multicomponent, green protocol to access 4, 7-dihydrotetrazolo [1,5-*a*] pyrimidines and 5,6,7,9-tetrahydrotetrazolo[5,1-*b*]quinazolin-8(4*H*)-ones using PEG-400 under microwave irradiation, Synthetic Communications.2019;49:3181-3190.

[150] Basha S F, Prasad T N, Gudise V B, Kumar V S, Mulakayala N, Anwar S. An efficient, multicomponent, green protocol to access 4, 7-dihydrotetrazolo [1,5-*a*] pyrimidines and 5,6,7,9-tetrahydrotetrazolo[5,1-*b*]quinazolin-8(4*H*)-ones using PEG-400 under microwave irradiation, Synthetic Communications.2019;49:3181-3190.

[151] Ghorbani□Vaghei R, Alavinia S, Sarmast N. Fe_3O_4@SiO_2@propyl-ANDSA: A new catalyst for the synthesis of tetrazoloquinazolines. Appl Organometal Chem. 2017;32:e4038.

[152] Raju C, Madhaiyan K, Uma R, Sridhar R, Ramakrishnab S. Antimicrobial and antioxidant activity evaluation of tetrazolo[1,5-*a*]pyrimidines: A simple diisopropylammonium trifluoroacetate mediated synthesis. RSC Advances. 2012;2:11657-11663.

[154] Zeng L, Cai C. Iodine Catalyzed One-Pot Multicomponent Synthesis of a Library of Compounds Containing Tetrazolo[1,5-*a*]pyrimidine Core J. Comb. Chem. 2010;12:35-40.

[154] Zeng L, Cai C. Iodine Catalyzed One-Pot Multicomponent Synthesis of a Library of Compounds Containing Tetrazolo[1,5-*a*]pyrimidine Core J. Comb. Chem. 2010;12:35-40.

[155] Hassankhani A, Gholipour B, Rostamnia S, Zarenezhad E, Nouruzi N, Kavetskyy T, Khalilov R, Shokouhimeh M. Sustainable design and novel synthesis of highly recyclable magnetic carbon containing aromatic sulfonic acid: Fe_3O_4@C/Ph—SO_3H as green solid acid promoted regioselective synthesis of tetrazoloquinazolines. Appl Organomet Chem. 2021;35:e6346.

[156] Kour P, Singh V P, Khajuria B, Singh T, Kumar A. Al(III) chloride catalyzed multi component domino strategy: Synthesis of library of dihydrotetrazolo[1,5-*a*]pyrimidines and tetrahydrotetrazolo[1,5-*a*]quinazolinones. Tetrahedron Letters. 2017;58:4179-4185.